| Original language | English (US) |
|---|---|
| Pages (from-to) | 2566-2568 |
| Number of pages | 3 |
| Journal | Mayo Clinic Proceedings |
| Volume | 95 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2020 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Mayo Clinic Proceedings, Vol. 95, No. 11, 11.2020, p. 2566-2568.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs—The 4P Model
AU - Norris, David C.
AU - Sen, Shiraj
AU - Groisberg, Roman
AU - Subbiah, Vivek
N1 - Funding Information: Potential Competing Interests: Dr Norris operates a scientific and statistical consultancy focused on precision medicine methodologies such as those advanced in this letter. Dr Sen reports research funding for clinical trials (paid in full to his institution) from Loxo, Jacobio, Exelixis, GlaxoSmithKline, BioAtla, Xencor, Epizyme, Abbisko Therapeutics, Fujifilm, Synthorx, Turning Point Therapeutics, Daiichi-Sankyo, and Tesaro. Dr Groisberg reports consultancy/advisory board fees from Regeneron. Dr Subbiah reports research funding/grant support for clinical trials from Roche/Genentech, Novartis, Bayer, GlaxoSmithKline, NanoCarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berg Health, Incyte, Fujifilm, PharmaMar, D3, Pfizer, MultiVir, Amgen, AbbVie, Alfasigma, Agensys, Boston Biomedical, Idera Pharmaceuticals, Inhibrx, Exelixis, Blueprint Medicines, Loxo Oncology, MedImmune, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, National Cancer Institute Cancer Therapy Evaluation Program, The University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, and Boston Pharmaceuticals as well as travel support from Novartis, Pharma Mar, American Society of Clinical Oncology, European Society for Medical Oncology, Helsinn, and Incyte. He reports consultant/advisory board fess from Helsinn, Loxo Oncology/Eli Lilly, R-PHARM US, Incyte, QED Pharmaceutical Services, MedImmune, and Novartis. He also reports support from Medscape.
PY - 2020/11
Y1 - 2020/11
UR - http://www.scopus.com/inward/record.url?scp=85095459184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095459184&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2020.09.009
DO - 10.1016/j.mayocp.2020.09.009
M3 - Letter
C2 - 33153645
AN - SCOPUS:85095459184
SN - 0025-6196
VL - 95
SP - 2566
EP - 2568
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 11
ER -